The trials were testing the efficacy of Keytruda, used in combination with standard multiple myeloma medications, to treat the blood cancer.
The FDA paused the trial after more patient deaths occurred among multiple myeloma patients taking the Keytruda immunotherapy regimen. Available data shows the risks of combining Keytruda with existing multiple myeloma drugs outweigh any possible benefits for this patient population, the FDA said.
At present, Keytruda is only approved to treat one form of blood cancer — classical Hodgkin’s lymphoma.
More articles on supply chain:
Britain looks to work with EU on drug regulation post-Brexit
St. Francis Medical Center receives Premier’s Supply Chain Excellence Award
Pharma looks to AI for streamlined drug development
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
